These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25366584)

  • 1. Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease.
    Hassan S; Petrella TM; Zhang T; Kamel-Reid S; Nordio F; Baccarelli A; Sade S; Naert K; Habeeb AA; Ghazarian D; Wright FC
    Ann Surg Oncol; 2015; 22(6):1950-8. PubMed ID: 25366584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
    Boyd KU; Wehrli BM; Temple CL
    J Surg Oncol; 2011 Dec; 104(7):711-7. PubMed ID: 21744347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
    Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
    Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.
    Joseph RW; Eckel-Passow JE; Sharma R; Liu P; Parker A; Jakob J; Buchbinder E; Bassett RL; Davies MA; Hwu P; Atkins MB; Sullivan RJ
    J Immunother; 2012; 35(9):711-5. PubMed ID: 23090080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
    Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
    Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma.
    Khoury S; Knapp GC; Fyfe A; Monzon J; Temple-Oberle C; McKinnon GJ
    J Cutan Med Surg; 2021; 25(4):364-370. PubMed ID: 33529083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
    Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
    J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic significance of DNA ploidy in disseminated malignant skin melanoma and the effectiveness of interleukin-2 (IL-2) treatment].
    Novik AV; Novik BI; Moiseenko VM
    Vopr Onkol; 2007; 53(2):164-9. PubMed ID: 17663169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Long GV; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Kefford RF; Thompson JF; Scolyer RA
    Ann Surg Oncol; 2012 Jun; 19(6):1782-9. PubMed ID: 22350600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].
    Dehesa LA; Vilar-Alejo J; Valerón-Almazán P; Carretero G
    Actas Dermosifiliogr; 2009 Sep; 100(7):571-85. PubMed ID: 19715642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
    Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
    Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
    Hua C; Boussemart L; Mateus C; Routier E; Boutros C; Cazenave H; Viollet R; Thomas M; Roy S; Benannoune N; Tomasic G; Soria JC; Champiat S; Texier M; Lanoy E; Robert C
    JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma.
    Coventry BJ; Kroon HM; Giles MH; Henderson M; Speakman D; Wall M; Barbour A; Serpell J; Paddle P; Coventry AG; Sullivan T; Smithers BM
    J Surg Oncol; 2014 Jun; 109(8):780-5. PubMed ID: 24634160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
    Uprety D; Bista A; Chennamadhavuni A; Niroula A; Jafri SIM; Smith A; Arjyal L
    Melanoma Res; 2018 Feb; 28(1):56-60. PubMed ID: 29023264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenia as a prognostic factor among patients with stage III melanoma.
    Sabel MS; Lee J; Cai S; Englesbe MJ; Holcombe S; Wang S
    Ann Surg Oncol; 2011 Dec; 18(13):3579-85. PubMed ID: 21822551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review.
    Byers BA; Temple-Oberle CF; Hurdle V; McKinnon JG
    J Surg Oncol; 2014 Nov; 110(6):770-5. PubMed ID: 24996052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
    Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
    Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.